Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications. [PDF]
J Clin MedAlmaimani M, Alamri SA.
europepmc +1 more source
Navigating the potassium dilemma: a qualitative study of nephrologists' strategies for renin-angiotensin-aldosterone system inhibitor preservation and hyperkalaemia management in Spain. [PDF]
PLoS OneGimenez-Stamminger N +3 more
europepmc +1 more source
Related searches:
Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection
Current Problems in Cardiology, 2022The renin-angiotensin-aldosterone system is a neurohormonal system responsible for maintaining homeostasis of fluid regulation, sodium balance, and blood pressure. The complexity of this pathway enables it to be a common target for blood pressure and volume-regulating medications. The mineralocorticoid receptor is one of these targets, and is found not
Dominic Parfianowicz +9 more
openaire +2 more sources
Protective effects of naringenin in cardiorenal syndrome
Journal of Surgical Research, 2016Cardiorenal syndrome is a complicated and bidirectional interrelationship between the heart and kidneys. Naringenin (NG) is a naturally occurring flavonoid possessing various biological and pharmacological properties.We tested whether NG could improve cardiac and renal function in a rat model of cardiorenal syndrome.The results showed that NG ...
Yan, Liu, Wenjun, An, Aibao, Gao
openaire +2 more sources
Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
Current Diabetes Reviews, 2023Abstract: Cardiovascular disease and renal complications raise the risk of death and morbidity in patients with type 2 diabetes (T2D). Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a novel class of glucose-lowering drug that increases urine glucose excretion while decreasing blood glucose levels in type 2 diabetes patients by inhibiting ...
Somayeh, Nazari, Hossein, Mirkhani
openaire +2 more sources
Cardiorenal Protection in Diabetes Mellitus
2011Diabetic cardiomyopathy is a major complication of diabetes that is independent of high blood pressure or atherosclerosis. In addition to diastolic dysfunction, the diabetic heart is more susceptible to oxidative stress. Hyperglycemia (HG) dominates the pathophysiology and clinical course of type 1 and type 2 Diabetes.
Himanshu Vashistha +2 more
openaire +1 more source
Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM
Annals of Pharmacotherapy, 2022Objective: To describe the pharmacology, clinical and safety evidence, and relevance to clinical practice of finerenone. Data Sources: A literature search was conducted utilizing PubMed, MEDLINE, and clinicaltrials.gov with search ...
Allissa Long, Marissa Salvo
openaire +2 more sources
Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update
American Journal of Kidney Diseases, 2009The renin-angiotensin system (RAS) has an important role in hypertension and the continuum of cardiovascular and kidney disease. The inhibition of this system, either with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), has been shown to be beneficial for cardiorenal protection.
ARICI, MUSTAFA, ERDEM, YUNUS
openaire +3 more sources
Protective cardiorenal effects of spironolactone in a rodent model of polycystic kidney disease
Clinical and Experimental Pharmacology and Physiology, 2015SummaryStudies were performed to examine the contribution of aldosterone to the pathogenesis of cardiovascular and renal disease in a rodent model of genetic kidney disease. Spironolactone (20 mg/kg per day) was administered in water to mixed sex Lewis Polycystic Kidney (LPK) rats (n = 20) and control Lewis rats (n = 27) from 4 to 12 weeks of age.
Thamarasee M, Jeewandara +5 more
openaire +2 more sources
Cardiorenal protection in diabetes.
Heart disease (Hagerstown, Md.), 2002Diabetes is twice as common in hypertensive patients than in the general population, and is a major cause of cardiovascular morbidity. Diabetes is the most common cause of end-stage renal disease in the United States, and is primarily responsible for the 9% increase in prevalence of end-stage renal disease during the past 10 years.
openaire +1 more source